PhosphoGam

Executive Summary

PhosphoGam is a private San Diego-based biotechnology company developing a novel non-viral, allogeneic CAR-T cell therapy platform leveraging gamma/delta-T (γδ-T) cells and mRNA electroporation. By eliminating the need for viral vectors and enabling off-the-shelf manufacturing, the company aims to reduce production costs by approximately 90% compared to conventional autologous CAR-T therapies while maintaining potent antitumor activity. The γδ-T cell backbone offers intrinsic tumor-targeting capabilities and a favorable safety profile, potentially overcoming key limitations of current CAR-T products, including high cost, manufacturing complexity, and patient-specific variability. With a focus on hematologic malignancies and solid tumors, PhosphoGam's platform could expand access to cell therapy across a wider patient population. Despite being in a preclinical or early clinical stage, the company's technology has attracted attention for its scalability and cost reduction potential. However, it faces competition from other allogeneic CAR-T approaches and must demonstrate clinical proof-of-concept to validate its advantages.

Upcoming Catalysts (preview)

• Q2 2027Initiation of First-in-Human Phase I Trial60% success
• Q4 2026Strategic Partnership with Major Pharma40% success
• Q3 2026Series B or C Financing Round70% success